Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Clesitamig, an antibody targeting DLL3 × CD3&TNFRSF9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cizutamig, an antibody targeting BCMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atenastobart, an antibody targeting 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sirtratumab, an antibody targeting SLITRK6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Encelimab, an antibody targeting LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Demupitamab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Runimotamab, an antibody targeting HER2 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ispectamab, an antibody targeting BCMA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Inezetamab, an antibody targeting CD40 × MSLN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enuzovimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tilvestamab, an antibody targeting AXL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bapotulimab, an antibody targeting ILDR2.